Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

Fennec Pharmaceuticals Inc., which operates as a commercial stage specialty pharmaceutical company, has officially scheduled the release of its financial results for the first quarter of 2026. According to the announcement made from Research Triangle Park, North Carolina, the company will publish these results on Thursday, May 14, 2026. This disclosure is set to take place before the opening of the U.S. financial markets on that day. Fennec is a dual-listed entity, maintaining its presence on the NASDAQ under the ticker symbol FENC and on the Toronto Stock Exchange under the symbol FRX.^[1][2]

Following the release of the first quarter financial data, Fennec's management team will host a conference call to discuss the results and provide further details on the company's performance. The initial announcement regarding this reporting schedule was issued on May 7, 2026, through Globe Newswire. As a specialty pharmaceutical firm, Fennec focuses on commercial-stage developments, and the upcoming call will allow management to address the company's progress during the first three months of the 2026 calendar year.^[1][2]